1.03BMarket Cap-2905P/E (TTM)
15.460High14.990Low170.07KVolume15.280Open15.280Pre Close2.59MTurnover0.31%Turnover RatioLossP/E (Static)68.29MShares19.71052wk High-4.40P/B837.73MFloat Cap6.06552wk Low--Dividend TTM55.66MShs Float64.540Historical High--Div YieldTTM3.08%Amplitude5.840Historical Low15.252Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
$Phathom Pharmaceuticals (PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
No comment yet